Stefan Kaulfuss

USPTO Granted Patents = 13 (Patent Applications = 10)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 12 (Patent Applications = 21)

Average Co-Inventor Count = 15.9

ph-index = 3

Forward Citations = 50(Granted Patents)

Location History:

Berlin, DE (2017 - 2019)
Leverkusen, DE (2022 - 2024)

Company Filing History:

11 out of 378

Bayer Pharma Aktiengesellschaft

patents

7 out of 443

The Broad Institute, Inc.

patents

7 out of 12,157

Bayer Aktiengesellschaft

patents

4. 1 out of 1,206

Dana-farber-cancer Institute Inc.

patents

5. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

13 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12227501 - 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors (2025-02-18),

2. 12152041 - Macrocyclic fluorine substituted indole derivatives (2024-11-26),

3. 11891404 - Substituted macrocyclic indole derivatives (2024-02-06),

4. 11478451 - Macrocyclic chlorine substituted indole derivatives (2022-10-25),

5. 11447504 - Macrocyclic chlorine substituted indole derivatives (2022-09-20),

6. 11440923 - Substituted macrocyclic indole derivatives (2022-09-13),

7. 11401278 - Macrocyclic indole derivatives (2022-08-02),

8. 11286263 - Macrocyclic fluorine substituted indole derivatives (2022-03-29),

9. 10442772 - Benzimidazol-2-amines as mIDH1 inhibitors (2019-10-15),

10. 10137110 - 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors (2018-11-27),

11. 9957235 - Benzimidazol-2-amines as mIDH1 inhibitors (2018-05-01),

12. 9951027 - Benzimidazol-2-amines as MIDH1 inhibitors (2018-04-24),

13. 9708311 - Benzimidazole derivatives as EP4 antagonists (2017-07-18),

Title: Innovator Spotlight - Stefan Kaulfuss: Pioneering Discoveries in Pharmaceutical Innovations

Introduction:

Stefan Kaulfuss, a brilliant inventor based in Leverkusen, Germany, has made significant contributions to the field of pharmaceutical innovations. With a remarkable portfolio of 11 patents, Stefan's groundbreaking work has propelled advancements in the treatment of hyperproliferative disorders.

Latest Patents:

Stefan Kaulfuss's latest patents showcase his expertise in developing novel pharmaceutical compounds. The first patent pertains to substituted macrocyclic indole derivatives, emphasizing their efficacy in treating hyperproliferative disorders. The second patent focuses on macrocyclic chlorine-substituted indole derivatives, highlighting their potential as essential components in pharmaceutical compositions.

Career Highlights:

During his illustrious career, Stefan Kaulfuss has been associated with esteemed organizations at the forefront of pharmaceutical research. He has lent his expertise to companies like Bayer Pharma Aktiengesellschaft and The Broad Institute, Inc., where he has played a pivotal role in driving innovation and scientific discovery.

Collaborations:

Stefan Kaulfuss's collaborative spirit is reflected in his work alongside accomplished peers in the industry. Notable colleagues such as Joachim Kuhnke and Laura Furst have worked closely with Stefan, contributing to a dynamic environment of shared knowledge and expertise.

Conclusion:

In conclusion, Stefan Kaulfuss stands as a beacon of innovation in the realm of pharmaceutical inventions. His dedication to advancing medical treatments for hyperproliferative disorders has left an indelible mark on the field. With a robust portfolio of patents and a legacy of impactful collaborations, Stefan Kaulfuss continues to shape the landscape of pharmaceutical innovations for the better.

This text is generated by artificial intelligence and may not be accurate.